Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 81.44% | -2.07% | -42.79% | -173.13% | 20.71% |
| Total Depreciation and Amortization | 5.71% | -14.89% | -4.91% | 50.43% | -48.78% |
| Total Amortization of Deferred Charges | 0.00% | -35.96% | 790.00% | 0.00% | -9.09% |
| Total Other Non-Cash Items | -100.09% | -8.99% | 125,050.00% | 100.68% | -189.63% |
| Change in Net Operating Assets | -28.68% | 144.90% | -294.57% | -122.28% | 341.87% |
| Cash from Operations | -46.50% | 152.45% | 37.83% | -298.28% | 225.41% |
| Capital Expenditure | 9.52% | -0.80% | 17.22% | 36.02% | 15.41% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | 91.05% |
| Cash from Investing | 39.68% | -107.33% | 1,806.62% | 66.74% | 83.28% |
| Total Debt Issued | -- | -- | -- | -- | 51.26% |
| Total Debt Repaid | 62.94% | 91.35% | -5,807.14% | 1.18% | -1.19% |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | 0.00% | 50.00% | 90.48% | -425.00% | -33.33% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 110.93% | 91.17% | -4,537.14% | -102.97% | 53.99% |
| Foreign Exchange rate Adjustments | -236.36% | 283.33% | -200.00% | -118.18% | 210.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | 200.00% | -- | -- |
| Net Change in Cash | 3,087.50% | 99.77% | -60.83% | -152.89% | 442.37% |